Greenwich Lifesciences Inc (GLSI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $219.29M
Last updated: Nov 17, 2026 at 11:05 AM ET
Greenwich Lifesciences Inc (GLSI) Competitors
The companies most similar to Greenwich Lifesciences are Galectin Therapeutics (GALT), Lineage Cell Therapeutics (LCTX) and Palisade Bio (PALI). By market cap, Greenwich Lifesciences ranks 6th of the 13 companies on this page; Galectin Therapeutics (GALT) is the largest at $307.59M.
Peer Comparison
GLSI's revenue growth of 0.0% is above the peer median of -30.5%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Greenwich Lifesciences (GLSI) | $219.29M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Galectin Therapeutics Inc (GALT) | $307.59M | N/A | N/A | 0.0% | 671.1% | 0.0% | 0.00% |
| Lineage Cell Therapeutics Inc (LCTX) | $231.35M | N/A | 18.7x | 16.2% | -6.7% | -61.0% | 0.00% |
| Palisade Bio Inc (PALI) | $201.01M | N/A | 436.8x | 0.0% | N/A | 0.0% | 0.00% |
| Zentalis Pharmaceuticals Llc (ZNTL) | $167.05M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Sol Gel Technologies Ltd (SLGL) | $180.46M | N/A | 125.4x | 0.0% | N/A | -96.6% | 0.00% |
| Century Therapeutics Inc (IPSC) | $299.63M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| SAB Biotherapeutics Inc (SABS) | $266.66M | N/A | N/A | 0.0% | N/A | -62.4% | 0.00% |
| Nautilus Biotechnology Inc (NAUT) | $295.50M | N/A | 630.2x | 0.0% | N/A | 0.0% | 0.00% |
| Pyxis Oncology Inc (PYXS) | $188.98M | N/A | 11.6x | 0.0% | N/A | 0.0% | 0.00% |
| Compass Therapeutics Inc. (CMPX) | $139.35M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| MacroGenics Inc (MGNX) | $140.60M | N/A | 1.2x | -36.6% | -108.7% | -64.8% | 0.00% |
| Cellectis SA (CLLS) | $118.86M | N/A | 1.8x | 0.0% | -74.1% | -85.4% | 0.00% |
| Peer median | $195.00M | N/A | 18.7x | 0.0% | -40.4% | -30.5% | 0.00% |
Similar Companies
These are the 12 companies most similar to Greenwich Lifesciences, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Galectin Therapeutics Inc (GALT) | Galectin Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to the research and development of therapies for fibrotic... | GALT competitors |
| Lineage Cell Therapeutics Inc (LCTX) | Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment... | LCTX competitors |
| Palisade Bio Inc (PALI) | Leading BioSciences, Inc. develops therapies to improve human health through therapeutic protection of the gastrointestinal mucosal barrier. | PALI competitors |
| Zentalis Pharmaceuticals Llc (ZNTL) | Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapies for the treatment... | ZNTL competitors |
| Sol Gel Technologies Ltd (SLGL) | Sol-Gel Technologies Ltd., a specialty clinical-stage pharmaceutical company, is focused on developing and commercializing topical dermatological... | SLGL competitors |
| Century Therapeutics Inc (IPSC) | Century Therapeutics Inc. (Ticker: IPSC) is a leading biotechnology company specializing in allogenic cell therapy... | IPSC competitors |
| SAB Biotherapeutics Inc (SABS) | SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. | SABS competitors |
| Nautilus Biotechnology Inc (NAUT) | Nautilus Biotechnology, Inc., a development-stage life sciences company, is dedicated to creating platform technology to quantify and unlock proteome... | NAUT competitors |
| Pyxis Oncology Inc (PYXS) | Pyxis Oncology, Inc., a preclinical biotechnology company, is dedicated to developing antibody-drug conjugate (ADC) and monoclonal antibody (mAb)... | PYXS competitors |
| Compass Therapeutics Inc. (CMPX) | Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapies to treat multiple... | CMPX competitors |
| MacroGenics Inc (MGNX) | MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapies to treat cancer in the United States. | MGNX competitors |
| Cellectis SA (CLLS) | Cellectis SA, a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T cells that express chimeric antigen receptors... | CLLS competitors |
Frequently Asked Questions About GLSI
Who are Greenwich Lifesciences' main competitors?
The companies most similar to Greenwich Lifesciences include Galectin Therapeutics (GALT), Lineage Cell Therapeutics (LCTX), Palisade Bio (PALI), Zentalis Pharmaceuticals Llc (ZNTL) and Sol Gel Technologies (SLGL), listed from the closest match.
Who is Greenwich Lifesciences' biggest competitor?
Galectin Therapeutics (GALT) is both the largest of the similar companies at $307.59M and the closest match by business profile, size, sector and industry.
How does GLSI stock compare with its competitors?
GLSI's net margin is 0.0% against a peer median of 0.0%.
Which of Greenwich Lifesciences' competitors pays a higher dividend?
Greenwich Lifesciences pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Greenwich Lifesciences bigger than its competitors?
No. Greenwich Lifesciences is 6th by market cap among the 13 companies on this page; the largest is Galectin Therapeutics (GALT) at $307.59M.
GLSI pages: Overview, Earnings, Forecast, Financials, Competitors